ARCHIVES

In Brief: FDA’s Tabor To Head Biological Carcinogenesis in DCE; Steve Larson to Leave NIH for Memorial

This article is from The Cancer Letter archive.

Vol. 14 No. 18 | April 29, 1988

Download PDF Visit The Full Archive

Related Articles

In Brief: Curran Moves From Fox Chase To Jefferson; Groundbreaking From UNC Lineberger Center

December 2, 1994

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

August 9, 1991

Other ASCO Plenary Papers: Long Awaited Chemotherapy Results

June 12, 1992

DCE Board Delays Decision On New Collaborative Groups In Chemoprevention

November 30, 1984

Wilex, Fox Chase, Begin Trial Of WX-UK1 Targeting Invasion

May 28, 2004

Breast Cancer Treatment Studies Need Standard Definitions – Carbone

May 10, 1974